User:SDZeroBot/NPP sorting/STEM/Chemistry: Difference between revisions

Content deleted Content added
SDZeroBot (talk | contribs)
Updating report
SDZeroBot (talk | contribs)
Updating report
(24 intermediate revisions by the same user not shown)
Line 1:
{{User:SDZeroBot/NPP sorting/header|count=1420|date=1831 August 2025|ts=1301:5046, 1831 August 2025 (UTC)}}
 
{| class="wikitable sortable"
Line 9:
! scope="col" style="width: 10em;" | Creator (# edits)
! scope="col" style="width: 4em;" | Notes
|-
| 2024-01-15
| [[PlutoniumGadolinium(III) phosphateselenate]] <small>(Chemical compound)</small>
| Gadolinium(III) selenate is an inorganic compound with the [[chemical formula]] Gd<sub>2</sub>(SeO<sub>4</sub>)<sub>3</sub>. It exists as the anhydrate and octahydrate. The octahydrate transforms into the anhydrate when heated to 130&nbsp;°C.
| Stub
| data-sort-value=257122447 | [[Special:Contribs/MahmoudalrawiPraseodymium-141|MahmoudalrawiPraseodymium-141]] (257122447)
|
|-
| 20252024-0801-11
| [[ErbiumSamarium(III) carbonateantimonide]] <small>(Chemical compound)</small>
| Samarium antimonide is a binary inorganic compound of [[samarium]] and [[antimony]] with the formula SmSb. It forms crystals.
| Stub
| data-sort-value=410522447 | [[Special:Contribs/Laura240406Praseodymium-141|Laura240406Praseodymium-141]] (410522447)
|
|-
| 2024-01-18
| [[Porous polymer]]
| Porous polymers are a class of [[porous media]] materials in which [[monomer]]s form [[2D polymer|2D]] and [[3D polymers]] containing angstrom- to nanometer-scale pores formed by the arrangement of the monomers. They may be either crystalline or amorphous. Subclasses include [[covalent organic framework]]s (COFs), [[hydrogen-bonded organic framework]]s (HOFs), [[metal-organic framework]]s (MOFs), and [[porous organic polymer]]s (POPs).
| Start
| data-sort-value=8895 | [[Special:Contribs/Michael7604|Michael7604]] (8895)
|
|-
| 2024-01-22
| [[SoziniberceptPraseodymium monoselenide]] <small>(PharmaceuticalChemical compound)</small>
| Erbium(III)Praseodymium carbonatemonoselenide is an [[erbium]]a compound with the [[chemical formula]] {{chem2|Er2(CO3)3}}PrSe. It forms crystals.
| Stub
| data-sort-value=22447 | [[Special:Contribs/Praseodymium-141|Praseodymium-141]] (22447)
|
|-
| 2024-01-26
| [[Iron(III) selenite]] <small>(Chemical compound)</small>
| Iron(III) selenite is an inorganic compound with the chemical formula Fe<sub>2</sub>(SeO<sub>3</sub>)<sub>3</sub>. It exists anhydrous form and as various hydrates. The heptahydrate is produced by the reaction of [[ferric chloride]] and [[selenous acid]] (or [[sodium selenite]]) at a pH of 1.05.
| Start
| data-sort-value=22447 | [[Special:Contribs/Praseodymium-141|Praseodymium-141]] (22447)
|
|-
| 2024-11-10
Line 14 ⟶ 49:
| Qing-Yun Chen ({{zh|s=陈庆云|p=Chén Qìngyún}}; 25 January 1929 – 2 March 2023) was a Chinese [[organic chemist]] and member of the [[Chinese Academy of Sciences]], specializing in the field of organic fluorine chemistry.
| Start
| data-sort-value=83288392 | [[Special:Contribs/Tokisaki Kurumi|Tokisaki Kurumi]] (83288392)
|
|-
| 20252024-0501-3110
| [[Fudosteine]] <small>(Chemical compound)</small>
| [[Musahaqah]]
| Fudosteine (Cleanal) is a [[mucolytic agent]]. In Japan, it is approved for the treatment of [[bronchial asthma]], [[chronic bronchitis]], [[pulmonary emphysema]], [[bronchiectasis]], [[pulmonary tuberculosis]], [[pneumoconiosis]], atypical [[mycobacterial disease]], and [[diffuse panbronchiolitis]].
| Musaheqeh ({{Langx|ar|مساحقه}}) is a legal and religious term. In [[Fiqh|Islamic jurisprudence]] ([[fiqh]]) and under the [[Islamic Penal Code of Iran]], musaheqeh refers to a situation in which an adult, mentally competent, and consenting [[woman]] brings her [[Sex organ|genitalia]] into contact with the genitalia of another woman.
| Stub
| data-sort-value=26485014 | [[Special:Contribs/JesusisGreat7Innerstream|JesusisGreat7Innerstream]] (26485014)
|
|-
Line 35 ⟶ 70:
| <sup>177</sup>Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.
| C
| data-sort-value=55665704 | [[Special:Contribs/Noxoug1|Noxoug1]] (55665704)
|
|-
| 2025-08-08
| [[Sozinibercept]] <small>(Pharmaceutical compound)</small>
| Sozinibercept was an [[investigational drug]] intended to be used to treat certain eye conditions such as wet [[age-related macular degeneration]] (AMD). It is administered [[Intravitreal injection|intravitreally]] in combination with other Anti-[[VEGF-A]] including [[aflibercept]], [[faricimab]], [[ranibizumab]], and [[bevacizumab]].
| Start
| data-sort-value=2571 | [[Special:Contribs/Mahmoudalrawi|Mahmoudalrawi]] (2571)
|
|-
Line 49 ⟶ 77:
| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.
| C
| data-sort-value=55665704 | [[Special:Contribs/Noxoug1|Noxoug1]] (55665704)
|
|-
Line 56 ⟶ 84:
| Vatinoxan, originally known as MK-467, is an [[Alpha-2_adrenergic_receptor#Antagonists|α<sub>2</sub>-adrenergic receptor antagonist]] used in veterinary medicine alongside [[Alpha-2_adrenergic_receptor#Agonists|α<sub>2</sub>-adrenergic receptor agonists]] to counteract [[vasoconstriction]] and [[hypertension]] while maintaining sedation. Vatinoxan does not cross the [[blood–brain barrier]] giving it a unique pharmacological profile compared to the other α<sub>2</sub>-adrenergic receptor antagonists and distinct clinical application.
| C
| data-sort-value=493499 | [[Special:Contribs/Sacristy|Sacristy]] (493499)
|
|-
| 20242025-1201-1719
| [[DazadrolFluorescence upconversion]] <small>(DazadrolUltrafast islaser anspectroscopic antidepressanttechnique)</small>
| Fluorescence upconversion (FU) is an [[Ultrafast laser spectroscopy|ultrafast laser spectroscopic]] technique. It is a variant of [[sum-frequency generation]] (of which the [[second-harmonic generation]] (SHG) is a special case) but applied to the detection of the incoherent [[fluorescence]]. It is therefore closely related to the [[Optical Kerr Gating]] (OKG) technique.
| Dazadrol is a synthetic [[antidepressant]] developed by [[Schering-Plough|Schering Corp]] in the late 1960s. It acts primarily as a [[noradrenaline reuptake inhibitor]], increasing concentrations of noradrenaline in the [[synaptic cleft]], which is believed to underlie its antidepressant effects.
| C
| data-sort-value=104 | [[Special:Contribs/Ozzwah|Ozzwah]] (104)
|
|-
| 2025-06-16
| [[Sefaxersen]] <small>(Antisense oligonucleotide therapy under development)</small>
| Sefaxersen (also known as RO7434656, RG6299, ISIS-696844 and IONIS-FB-LRx) is an investigational [[antisense oligonucleotide]] (ASO) drug developed by [[Roche Holding AG]] in partnership with [[Ionis Pharmaceuticals]]. It targets [[complement factor B]] (CFB) to treat [[complement system]]-mediated diseases, primarily [[IgA nephropathy]] (IgAN) and [[geographic atrophy]] (GA) secondary to [[age-related macular degeneration]].
| C
| data-sort-value=5704 | [[Special:Contribs/Noxoug1|Noxoug1]] (5704)
|
|-
| 2025-08-0818
| [[Jens Bruun de Neergaard]] <small>(Danish judge and landowner)</small>
| Jens Bruun de Neergaard (14 June 1742 – 22 April 1788) was a [[Denmark|Danish]] judge and landowner. He owned [[Svenstrup (manor house)|Svenstrup Manor]], at [[Borup, Køge|Broup]], [[Køge Municipality]], whouse present main building he constructed in the 1780s. On 31 May 1780, alongside his younger brother, Johan Thomas de Neergaard (1745–1806), he was ennobled by [[letters patent]].
| Start
| data-sort-value=88166 | [[Special:Contribs/Ramblersen2|Ramblersen2]] (88166)
|
|-
| 2025-08-04
| [[Hellenic Championship (Tennis)]] <small>(Tennis tournament)</small>
| The Hellenic Championship is an [[ATP 250 tournaments|ATP 250 tournament]] held in [[Athens]], [[Greece]]. The event is played on indoor [[hardcourt]] at the [[OAKA Basketball Arena]], a multi-purpose venue that was used for the [[2004 Summer Olympics]]. It replaces the [[Belgrade Open]] on the calendar and it is scheduled to debut in November 2025.
| Stub
| data-sort-value=2604021 | [[Special:Contribs/Mo18ekulaHaddad Maia fan|Mo18ekulaHaddad Maia fan]] (2604021)
|
|-
Line 73 ⟶ 122:
|
|-
| 2025-08-1227
| [[Erbium(III) sulfateFerrugine]] <small>(Chemical compound)</small>
| Ferrugine is a [[tropane alkaloid]] discovered in the basic [[extract]] of the Australian rainforest tree ''[[Darlingia ferruginea]]'' where it occurs in the leaves and stems. The structure has been [[Chemical_structure#Structural_elucidation|determined]] through [[spectroscopic analysis]] and confirmed by [[chemical synthesis]].
| Erbium(III) sulfate is an [[erbium]] compound with the [[chemical formula]] {{chem2|Er2(SO4)3}}. It is a pink crystalline salt, readily absorbing water to form an octahydrate. It is used as a [[Colourant|colorant]] in [[glass manufacturing]] and [[porcelain enamel]] glazes, as well as a [[dopant]] in the production of [[optical fiber]].
| Stub
| data-sort-value=4940 | [[Special:Contribs/Slavxe2.101.56.53|Slavxe2.101.56.53]] (494)
|
|-
| 2025-0108-1922
| [[FluorescenceZimei upconversionBu]] <small>(Ultrafast laser spectroscopic techniqueresearcher)</small>
| Zimei Bu, PhD is a protein chemist in the [[City College of New York]], where she is Professor of Chemistry and Biochemistry and Laboratory Director.
| Fluorescence upconversion (FU) is an [[Ultrafast laser spectroscopy|ultrafast laser spectroscopic]] technique. It is a variant of [[sum-frequency generation]] (of which the [[second-harmonic generation]] (SHG) is a special case) but applied to the detection of the incoherent [[fluorescence]]. It is therefore closely related to the [[Optical Kerr Gating]] (OKG) technique.
| CStub
| data-sort-value=10424 | [[Special:Contribs/OzzwahWang Walton|OzzwahWang Walton]] (10424)
|
|-
| 2025-0605-1604
| [[SefaxersenErythrocyte-based drug delivery]] <small>(Antisense oligonucleotide therapyDrug underdelivery developmentmethod)</small>
| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.
| Sefaxersen (also known as RO7434656, RG6299, ISIS-696844 and IONIS-FB-LRx) is an investigational [[antisense oligonucleotide]] (ASO) drug developed by [[Roche Holding AG]] in partnership with [[Ionis Pharmaceuticals]]. It targets [[complement factor B]] (CFB) to treat [[complement system]]-mediated diseases, primarily [[IgA nephropathy]] (IgAN) and [[geographic atrophy]] (GA) secondary to [[age-related macular degeneration]].
| C
| data-sort-value=55666 | [[Special:Contribs/Noxoug1DrugDelivery2025|Noxoug1DrugDelivery2025]] (55666)
|
|-
| 2025-08-11
| [[Plutonium(III) phosphate]] <small>(Chemical compound)</small>
| Plutonium(III) phosphate is an [[inorganic compound]] of [[plutonium]], with the molecular formula {{chem2|PuPO4}}. It is the trivalent plutonium salt of [[phosphoric acid]].
| Start
| data-sort-value=4105 | [[Special:Contribs/Laura240406|Laura240406]] (4105)
|
|-
| 20252004-0807-1529
| [[Figure of Insensitivity]]
| [[Erbium(III) carbonate]] <small>(Chemical compound)</small>
| Figure of Insensitivity (''F of I'') is an inverse scale of measure of the impact [[shock sensitivity|sensitivity]] of an [[explosive]] substance. In this particular context the term 'Insensitivity' refers to the likelihood of initiation/[[detonation]] by impact, [[friction]], [[electrostatic discharge]], application of [[flame]], etc.
| Erbium(III) carbonate is an [[erbium]] compound with the [[chemical formula]] {{chem2|Er2(CO3)3}}.
| Start
| data-sort-value=41050 | [[Special:Contribs/Laura24040620.133.0.11|Laura24040620.133.0.11]] (4105)
|
|}
<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] <sup>''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''</sup> at 1301:5046, 1831 August 2025 (UTC)</span>